The paracrine renal endothelin system has been implicated in acute and chronic kidney diseases. However, there are only few data about the expression of endothelin receptor subtypes and their impact on renal function in the normal rat kidney. Therefore, we analyzed the age-dependent expression of endothelin receptors (endothelin receptor A and B) using Scatchard analysis, in vitro and in vivo receptor autoradiography. Furthermore, we investigated the effects of the mixed (A/B) endothelin receptor antagonist bosentan on haemodynamic and renal function in conscious chronically instrumented rats. The renal endothelin receptor A and endothelin receptor B expression is age-dependent. The relative amount of endothelin receptor A significantly decreased with age, whereas the endothelin receptor B significantly increased with age. Compared to the other renal structures, a high endothelin receptor density (endothelin receptor B » endothelin receptor A) was seen in the renal tubules and even more in the glomeruli. Bosentan blocks both the pressor and depressor response of endothelin. Blocking of both endothelin receptor subtypes using bosentan without application of endothelin, on the other hand, did not alter blood pressure, heart rate, renal blood flow, water excretion or glomerular filtration rate, but significantly decreased sodium excretion.
Introduction
Endothelins (endothelin-1, endothelin-2 and endothelin-and differ in their binding affinity to endothelin isopep-3), a family of 21 amino acid peptides throught to regu-tides (endothelin receptor A: endothelin-1 ^ endothelinlate local vasomotor tone, are the most potent vasocon-2 » endothelin-3; endothelin receptor B: cndothclin-1 strictor substances yet identified. Endothelin-1 was the -endothelin-2 = cndothelin-3, endothelin receptor C: first of the isopeptides to be characterized in the super-endothelin-3 » endothelin-2 = endothelin-1) as well as natant of cultured vascular endothelial cells (1) . The bio-in their expression by different cell types. In addition, logical effects of endothelin are mediated by plasma-there are indications that there are also nuclear endomembrane-bound receptors. Three endothelin receptor thelin receptors (5) . Apart from possessing vasoactive subtypes (endothelin receptor A, B and recently C) have properties, endothelins have been shown to cause a wide been cloned (2, 3, 4) . Endothelin receptor C has not yet variety of biological activities in non-vascular tissues, been described in mammals. The endothelin receptors including the kidney (6) . The paracrine renal endothelin belong to the family of rhodopsin-like receptors with system has been implicated in pathogenesis of many dissevcn transmembrane domains coupled to a G-protein eases such as hypertension (7, 8) and impaired renal function in liver cirrhosis (9) . Data from pharmacological studies indicate that renal blood flow and tubular function are partially controlled by both the endothelin receptor A and endothelin receptor B (10) . However, little is known about the age-depedent expression, tissue distribution and physiology of endothelin receptor sur> types in the rat kidney. Therefore, the aim of our study was to analyze the age-dependent expression of endothelin receptor subtypes in the rat kidney using Scatchard analysis, in vitro and in vivo receptor autoradiography. Furthermore, we analyzed the effects of bosentan, an orally active, mixed (A/B) endothelin receptor antagonist (11), on mean arterial blood pressure, glomerular filtration rate, renal blood flow, heart rate and renal vascular resistance in conscious chronically instrumented rats. In addition, the effect of bosentan on water and sodium excretion was analyzed as well.
Materials and Methods

Materials
Male Wistar rats (WKY) were obtained from Mallegard, Denmark and fed a commercial diet (Altromin®, Altromin GmbH, Germany) and were given water ad libitum. 
Membrane preparation
Membranes were prepared according to Nambi et al. (12) . The rats were sacrificed, and the cortex and medulla were carefully dissected from each other. Approximately 150 mg of kidney medulla or cortex were homogenized at 4°C in 10ml of 20 mmol/1 NaHC0 3 using a motor-driven pestle homogenizes The homogenate was centrifuged at 4 °C for 15 min at 1000 g. The supernatant was decanted and centrifuged at 4 °C for 30 min at 40000 g. The pellet consisting of crude plasma membranes was resuspended in assay buffer (1 g/1 bacitracin, 100 mmol/1 Tris-HCl, 5 mmol/1 MgCl 2 , and 1 g/1 bovine serum albumin, pH 7.4) at a protein concentration of 200 mg/1.
Binding assay for endothelin receptor A and B
Binding studies were performed as previously described with some modifications (5) . In order to analyze the expression of endothelin receptor subtypes (endothelin receptor A, endothelin receptor B) in the kidney, binding assays were performed in the presence or absence of the subtype-specific endothelin receptor ligands BQ 123 (3 μηιοΐ/ΐ) and/or BQ 3020 (14) . The assay buffer for binding studies contained 1 g/1 bacitracin, 100 mmol/1 Tris-HCl, 5 mmol/l MgCl 2 , and 1 g/1 bovine serum albumin, pH 7.4. The total assay volume was 150 μΐ. The [ 125 I]endothelin-l tracer concentration was kept constant at 40000 counts per minutes and tube, while the concentration of unlabeled endothelin-1 was increased from 0 to 25 nmol/I (competition studies with "cold saturation"). Binding studies were performed at room temperature for 120 min. Nonspecific binding was assessed in the presence of excess endothelin-1 (5 μπΐοΐ/ΐ). After adding 1 ml of cold binding buffer, free and receptor-bound radioactivity was separated by centrifugation at 30000g (4°C) for 15 min, and the pellets thus obtained were washed two additional times with 1 ml of cold binding buffer.
125
I was counted in a Packard Gamma Counter (78% counting efficiency for 125 I).
Autoradiography of tissue endothelin receptor subtypes
In vivo autoradiography
After anesthesia by intraperitoneal administration of pentobarbital, the vena cava inferior was cannulated. In order to block the endothelin receptor A, the endothelin receptor B or both receptor subtypes BQ 123, BQ 3020 or BQ 123 and BQ 3020 (control) were injected into the vena cava inferior followed by an injection of [ I25 ]endothelin-l in saline 15 min thereafter. The dosages of endothelin-1, BQ 123 and BQ 3020 used did not alter the blood pressure during the experiment (data not shown). Fifteen min later the rats were sacrificed and the kidneys were perfused with 50 ml of icecold saline, followed by fixation with 25 g/1 glutaraldehyde/50 g/1 formalin. Thereafter the kidneys were removed and embedded in plastic material (Technovit®, Kulzer GmbH, Germany). The plastic blocks were cut into 2.5^m-thick sections, layered with photoemulsion (K5 nuclear trace emulsion, Ilford, England) and stained with hematoxylin and eosin. Evaluation was done by counting the silver grains. The number of silver grains in a given area was divided by the number of cell nuclei in the same area in order to consider possible differences in density of cells.
Contact autoradiography of tissue endothelin receptor subtypes was also performed. The kidneys were prepared as described above. The sections were apposed on X-ray film and exposed for 20-30 days under intensifying conditions.
In vitro autoradiography
The frozen kidneys were cut into 5 μιη thick sections with a microtome-cryostat. The sections were placed on precooled slides, airdried for 10 min and stored at -20 °C. Autoradiographic incubation was performed in the presence or absence of subtype specific endothelin receptor ligands BQ 123 (3 μηιοΐ/i) and/or BQ 3020 (3 μπιοΐ/ΐ). The slides were covered with 100 μΐ binding buffer (1 g/1 bacitracin, 100 mmol/1 Tris-HCl, 5 mmol/1 MgCl 2 , and 1 g/1 bovine serum albumin, pH 7.4) containing [ 125 I]endothelin-l in a concentration of 50 pmol/1 (4 MBq/1) and incubated in a moist chamber for 2 h at room temperature. Radioactivity was withdrawn by suction with a vacuum pump and the slides were washed 4 times for 10 min in 4 °C cold binding buffer. Finally the sections were fixed for 20 min in 50 g/1 formalin, 25 g/1 glutaraldehyde, 9 g/1 NaCl. To remove the salts the slides were dipped briefly in distilled water. Autoradiogramms with both endothelin receptor ligands (BQ 123, BQ 3020) served as a control. The sections were layered with photoemulsion (K5 nuclear trace emulsion, Ilford, England) and stained with hematoxylin and eosin. Evaluation was done by counting the silver grains.
Contact autoradiography of tissue endothelin'receptor subtypes
The kidneys were prepared as described above. The sections were mounted on X-ray film and exposed for 2 days under intensifying conditions. Eur J Clin Chem Clin Biochem 1995; 33 (No 8} Measurement of glomerular filtration rate, mean arterial blood pressure, heart rate and renal blood flow
Surgical procedures
One week prior to the acute experiments the rats were anaesthetized with ether and the femoral artery and vein catheters were implanted (3). Three'days before the start.of the experiments, flowprobes (1KB with implantable connector, Transsonic Systems Inc., Ithaca, NY) were chronically implanted around the left renal artery. Briefly, the left kidney was exposed by a retroperitoneal access. The renal artery was carefully dissected using an operating microscope to avoid damage to the renal nerves. The flowprobe was then placed around the artery and, after the best signal had been achieved, the probe was fixed in proper position using a small envelope of Merocel Op-Wipe® (Merocel Corp., Mystic, Connecticut, USA) covering the probe and the artery at the point of reflector attachment. To improve signal conductance, the envelope was filled with ultrasound gel. All catheters and cables were led subcutaneously to the rat's neck.
Circulatory measurements
Mean arterial blood pressure and heart rate were measured via the arterial line with a Statham pressure transducer P23Db and a Gould pressure processor coupled to a Gould Brush 2600 recorder. Renal blood flow was measured via the chronically implanted flowprobe with a transit time flowmeter (T106, Transonic System Inc., Ithaca, NY, USA) and continuously recorded on a Gould Brush 2600 recorder. The Transonic flowmeter system determines absolute volume flow by measuring the difference (picosecond range) between the upstream and downstream time of flight of a wide beam of ultrasound across the blood vessel (14) . The flowprobes were precalibrated by the producer and measured absolute blood flow with an accuracy of ± 2%. Renal vascular resistance was calculated as mean arterial blood pressure divided by renal blood flow.
Measurement of glomerular filtration rate
Glomerular filtration rate was measured using the inulin singleshot method (15) . The single-shot clearance was evaluated by displaying a two-compartment model with resolution of the plasma inulin concentrations into two rnonoexponential functions. The rats received an intravenous i.v. bolus injection of 150 mg of inulin (Inutest®). Blood samples for determination of serum mulin concentrations were drawn at 0, 15, 30, 90, 135 and 180 minutes after injection. Inulin was measured by a modified -fructosidase method (16) . Glomerular filtration rate is expressed as ml/min per 100 g body weight.
Effects of bosentan on the haemodynamic responses to endothelin
We tested the effects of increasing doses of the endothelin antagonist (bosentan or Ro 47-0203) on the haemodynamic responses to 200 ng endothelin (i. v.) in 16-week-old Wistar Kyoto rats. The rats received i.v. bolus injections of 200 ng endothelin 5 minutes after i.v. injections of vehicle. After baseline values had again been reached, the rats received increasing doses (0.3, 3, 10, 30, and 100 mg/kg) of bosentan, five minutes prior i.v. bolus injections of 200 ng endothelin, respectively. Bosentan was dissolved in water at a concentration of 15 g/1. The highest volume needed for this study was 2ml and did not alter blood pressure, heart rate or renal blood flow itself as shown by i. v. administration of vehicle. The animals were allowed to attain baseline values of all parameters measured between injections of endothelin with the respective endothelin antagonist. The conscious chronically instrumented rats received 200 ng of endothelin-1 and the doses (0.3, 3, 10, 30, and 100 mg/kg, respectively) of bosentan with breaks of 12 hours between the single experiments due to the well known tachyphylaxis after repeated injections of endothelin. Using this protocol we found no evidence for tachyphylaxis after repeated injections of endothelin with respect of blood pressure, renal blood flow and heart rate.
Effects of bosentan on glomerular filtration rate, mean arterial blood pressure, heart rate and renal blood flow
To examine the effects of bosentan on resting mean arterial blood pressure, heart rate, renal blood flow and renal vascular resistance in 16-week-old Wistar Kyoto rats, the rats received cumulative i. v. bolus injections of the mixed (A/B) endothelin receptor antagonist bosentan (3 mg/kg) every 15 minutes until a total load of 30 mg/ kg was obtained.
The experimental protocol for the determination of glomerular filtration rate was performed on two consecutive days. On day one 16-week-old male Wistar Kyoto rats received either an i.v. bolus injection of bosentan (100 mg/kg) or an i.v. bolus injection of vehicle (0.3 ml 9 g/1 NaCl), followed by an i. v. bolus injection of 150 mg inulin 5 minutes later. At 0, 15, 30, 90, 135 and 180 minutes after injection of inulin, blood samples (200 μΐ) were taken from the arterial catheter for determination of serum inulin concentrations. On day two the animals underwent the same protocol but received bosentan instead of vehicle and vica versa. Bosentan (micronized free sulphonamide) was used in suspension in 50 g/1 arabic gum (vehicle), prepared freshly and administered by gastric gavage with a polyethylene stomach tube (10 or 33.3 mg/kg body weight in 1.5 ml vehicle, respectively) by gastric gavage at the hours 0, 8, 16 for two days. Urine was collected for the determination of sodium, potassium and volume.
Results
Endothelin receptor binding experiments
Scatchard analysis revealed only one type of endothelin receptor A and B binding sites (data not shown). The endothelin receptor A and B binding constants (IQ) in the renal cortex were similar for 4-and 16-week-old Wistar Kyoto rats. On the other hand, the endothelin receptor B binding constants (K^) in the renal medulla increased in an age-dependent manner (tab. 1).
The endothelin receptor A density (B max ) in the whole kidney decreased with age, whereas the endothelin receptor B density (B max ) increased with age (p < 0.05 in all cases, tab. 1). The endothelin receptor B/endothelin receptor A ratio in the renal cortex is 0.60 in 4-weekold Wistar Kyoto rats and increased to 2.09 in 16-weekold Wistar Kyoto rats. The endothelin receptor B/endothelin receptor A ratio in the renal medulla is 1.38 in 4-week-old Wistar Kyoto rats and increased to 6.00 in 16-week-old Wistar Kyoto rats. These data are calculated from table 1. Non-specific binding was very low after blocking the endothelin receptors with BQ 123 and BQ 3020, as shown in figures 1-4. Receptor autoradiography showed that both subtypes (endothelin receptor A and endothelin receptor B) were present throughout the whole kidneys. Using in vivo autoradiography, the majority of binding sites in the kidney was observed in the cortex, mainly within the glomeruli. Both the endothelin receptor A and the endothelin receptor Β were homogeneously distributed throughout the glomeruli ( fig. 3) . By counting the silver grains, we observed a 4.6 ± 0.4 fold increased density of endothelin receptor B in the glomeruli (n = 6, ρ < 0.01) compared to the density of endothelin receptor A in 16-week-old Wistar Kyoto rats, whereas the density of endothelin receptor A is 1.9 radiography were equal. Contrary to the in vivo autoradiography, in vitro autoradiography revealed in high density of endothelin receptor B in medullary collecting ducts (figs. 1, 2) in 4 and moreover 16-week-old Wistar Kyoto rats. This was not an effect of length of tissue exposure to film, because in vivo and in vitro studies with a longer or shorter exposure time revealed the same differences. 
Effects of bosentan on the haemodynamic responses to endothelin
Intravenous bolus injections of 200 ng endothelin produced a biphasic blood pressor response: an initial shortlasting depressor effect was followed by a long-lasting blood pressure elevation. The changes in blood pressure were accompanied by reciprocal alterations in heart rate. In contrast, renal blood flow exhibited a monophasic response pattern (long-lasting decrease of renal blood flow) after endothelin i. v. Increasing doses of the endothelin antagonist induced a dose dependent blockade of the depressor effects to 200 ng endothelin i. v., maximal blockade was achieved after 10 mg/kg. Qualitatively the same was observed for the heart rate response during the depressor phase. In contrast, the pressor effect to endothelin i. v. was initially potentiated after increasing doses of the antagonist, with a maximum of potentiation after 3 mg/kg. After the highest dose of the endothelin antagonist used in this study (100 mg/kg) the pressor effect was blocked by 89.7%, whereas the heart rate response was blocked by 67.5%. The effects of the endothelin antagonist on the changes in renal blood flow to endothelin i. v. were qualitatively and quantitatively similar to the effects on the pressor response, with a maximum of potentiation after 3 mg/kg and a maximal inhibition after 100 mg/kg of 92.5%.
Effects of bosentan on renal blood flow, glomerular filtration rate, renal vessel resistance, heart rate and mean arterial blood pressure Cumulative i. v. bolus doses (3 mg/kg every 15 min) of the mixed (A/B) endothelin receptor antagonist did not alter renal blood flow, renal vessel resistance, heart rate or mean arterial blood pressure in 16-week-old Wistar Kyoto rats ( fig. 8) .
A bolus injection of the endothelin antagonist induced no alterations of glomerular filtration rate in 16-weekold Wistar Kyoto rats (1.21 ± 0.27 versus 1.19 ±0.15 ml/min per 100 g body weight). The bolus injection of bosentan caused a minor, non-significant reduction of mean arterial blood pressure by 3.6 ± 1.08 mmHg in Wistar Kyoto rats.
Effects of bosentan on water and sodium excretion
The mixed (A/B) endothelin receptor antagonist bosentan (100 mg/kg-d p.o.) significantly (p < 0.05) decreased sodium excretion in 16-week-old male Wistar Kyoto rats, whereas water excretion was not altered by bosentan (fig. 5) . The effects after giving a lower with the higher dosage (100 mg/kg · d), indicating that dosage of bosentan (30 mg/kg · d) on water and so-the lower dosage of bosentan also significantly dium excretion were not different (as analyzed by (p < 0.05) decreased sodium excretion, whereas water impaired t-test, data not shown) from those obtained excretion was not altered. 
Discussion
Age-dependent differences in renal endothelin receptor expression
Binding studies showed that the endothelin receptor B/ endothelin receptor A ratio in the kidney of Wistar Kyoto rats is age-dependent, suggesting age-dependent differences in the renal physiology of the paracrine endothelin system. Since it is well known that endothelin knock out mice have craniofacial abnormalities (17) , our data might indicate (but does not prove) that age-dependent expression of endothelin receptor subtypes play a major role in the pre-and postnatal development of the rat kidney.
In addition, the endothelin receptor B binding constant in the renal medulla of Wistar Kyoto rats is also agedependent. We suggest that structural alterations of endothelin receptor B (phosphorylation or glycosylation) may occur with age. N-glycosylation sites were identified in the outer cell domain of both endothelin receptor subtypes (2 9 3).
Receptor autoradiography
The highest endothelin receptor density in the rat kidney was seen in the glomeruli using in vivo or in vitro autoradiography ( fig. 3) , whereas in the human kidney the highest endothelin receptor density was present within the renal blood vessels and medullary tubules as shown by Karet et al. (29) using in vitro receptor autoradiography. In comparison to the rat kidney ( fig. 3 ) the glomeruli in the human kidney had a markedly lower density of endothelin receptors (29) . However, the endothelin receptor B/endothelin receptor A ratio in the kidney is similar in rats (tab. 1) and humans (29) as seen by Scatchard analysis.
The endothelin receptor B within the rat glomeruli seems to be located on the glomerular endothelial cells, as suggested by data from Fumy a et al. (18) . Using electron microscopic autoradiography, they found that the endothelin-1 binding sites in the kidney were preferably localized on the fenestrated endothelial cells of glomeruli and peritubular capillary endothelial cells. The glomerular endothelin receptor A is most probably expressed by mesangial cells (19, 20) .
On the other hand, our study clearly demonstrated different patterns of endothelin receptor subtype distribution in rat renal medulla depending on the method used (in vivo or in vitro autoradiography, figs. 1 and 2 ). Analyzing the total renal [ 125 I]endothelin-l binding this phenomena was also seen by Koseki et al. (31) . The reason for this discrepancy in our study and in the above mentioned study (31) between in vitro and in vivo receptor autoradiography is unknown, but there are two feasible explanations: i) even very low concentrations of endothelin receptorligands may alter the renal microcirculation in vivo resulting in alterations of radioligand distribution or ii) [ 125 ]endothelin-l access to the tissues is not the same in vitro or in vivo due to the hydrophobic nature of the receptor ligands.
In any case in vivo receptor autoradiography seems to be a suitable method for preferential labeling of vascular endothelin receptors, whereas in vitro autoradiography labels both vascular and non-vascular endothelin receptors.
Effects of bosentan on the haemodynamic responses to endothelin
The mixed endothelin receptor antagonist bosentan was chosen for physiological studies, because this antagonist is orally active thus being of clinical relevance, whereas most of the selective yet described endothelin receptor A and B antagonists are not orally active. Due to the short supply of bosentan, our analysis was limited to 16-week-old Wistar Kyoto rats. Bosentan is able to block in vivo both the pressor and depressor response to endothelin as shown in figure 6 and by others (11, 28) , indicating that bosentan is an endothelin receptor A and B antagonist. However, in contrast to Gardiner et al. (28) , our study revealed no effect of bosentan at a dosage of 30 mg/kg i. kg bosentan ( fig. 6 ), whereas the study of Gardiner et al. demonstrated a partial blockade of the endothelin-1 induced pressure effect after 30 mg/kg bosentan i.v. They suggested, but did not prove by a dose-dependent study, that the dose of bosentan used in their study (30 mg/kg) was insufficient to fully inhibit the haemodynamic effects of endothelin-1. In the present study we were able to demonstrate that the endothelin-1 induced pressure response was completely blocked after 100 mg/ kg bosentan i. v. (fig. 6 ). These minor differences concerning the bosentan dosage needed for complete blockage of the pressure response to endothelin-1 may be due to the different rat strains used in our study (Wistar Kyoto rats) and the study of Gardiner et al. (Long Evans rats).
The depressor response to endothelin is mediated by the endothelin receptor B-induced nitric oxide synthesis (21) . Based on pharmacological studies using selective endothelin receptor A or B ligands, it was shown that the pressor response to endothelin-1 in rats is mediated by both the endothelin receptor A and B. Warner et al. (22) suggested the terms endothelin receptor Bl to describe the endothelin receptor B that mediates endothelium-dependent nitric oxide-induced vasorelaxation and endothelin receptor B2 to describe the endothelin recep. tor B that mediates vasoconstriction. However, several points should be addressed in this context: tentiated after increasing doses of bosentan. This observation may also reflect the above-mentioned higher local concentrations of bosentan in the endothelin cell layer than in the smooth muscle cells of blood vessels contributing to blood pressure, since the inhibitory effect of bosentan on the pressor effect is reduced by the concomitant inhibitors of the depressor effect. Only after having blocked all the endothelin receptor B (endothelin receptor Bl), the net effect of bosentan resulted in lowering the mean arterial blood pressure.
iii) In contrast to systemic blood pressure and heart rate, renal blood flow exhibited a monophasic response pattern to endothelin (long-lasting decrease of renal blood flow without an initial increase of renal blood flow; fig. 7 ), suggesting that the endothelin receptor Bl mediated vasorelaxation is of minor importance or missing in the rat renal vascular beds. Effects of bosentan on mean arterial blood pressure, heart rate, renal blood flow, glomerular filtration rate, water and sodium excretion in 16-week-old Wistar Kyoto rats
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In contrast to deoxycorticosterone acetate-salt hypertensive rats (23) or spontaneously hypertensive rats (24), bosentan does not alter mean arterial blood pressure, heart rate, renal blood flow or glomerular filtration rate in 16-week-old Wistar Kyoto rats ( fig. 8 ), indicating that these parameters are not mainly controlled by the paracrine endothelin system in normotensive rats. It is also possible that the net effect of blocking both the endothelin receptor A and B resulted in no alterations of the above mentioned quantities. Therefore, subtype specific antagonists are necessary to answer this question. So- dium excretion, on the other hand, is significantly reduced by the endothelin receptor antagonist bosentan, indicating that the tubular sodium transport in the renal medulla is under the control of the renal endothelin system. Our data are in agreement with studies showing an increased urinary sodium excretion caused by intravenous administration of endothelin receptor agonists (endothelin-1) (25) . Some of these natriuretic effects of endothelin may be due to inhibition of sodium reabsorption in the renal collecting duct by action on both apical sodium entry and basolateral Na + /K + -ATPase (26, 27) . Intravenous administration of endothelin-1 or endothelin-3 also reduces water reabsorption in the rat kidney (25) . However, we did not see any effect on water excretion after blocking both the endothelin receptor A and B with bosentan, suggesting that the renal paracrine endothelin system in normotensive rats without exogenous stimulation plays a minor role in the regulation of water excretion, but is involved in the regulation of sodium excretion. The observed effects after intravenous endothelin administration on renal function (25, 26, 27 ) most probably reflect the situation in an activated paracrine system and therefore are different from the situation without exogenous stimulation.
With respect to heart rate and blood pressure our data are in agreement with a recent report by Teerlink et al. (30) . They also observed no significant changes in mean arterial blood pressure and heart rate in anesthetized open-chest dogs after blocking the endogenous endothelin system using bosentan.
In summary, this study showed that the renal endothelin receptor A and B expression is age-dependent. The relative amount of endothelin receptor A decreases significantly with age. The endothelin receptor B is the predominant endothelin receptor of the adult rat kidney. Compared to the other renal structures, a high endothelin receptor density (endothelin receptor A and B) was seen in the renal tubules and even more in the glomeruli. The mixed (A/B) endothelin receptor antagonist bosentan blocks both the pressor and depressor response of endothelin. Blocking of both endothelin receptor subtypes using bosentan without application of endothelin, on the other hand, did not alter blood pressure, heart rate, renal blood flow, water excretion and glomerular filtration rate, but significantly decreased sodium excretion.
